E-mail a Wiley Online Library Link

Derek R. Johnson, Heather E. Leeper and Joon H. Uhm Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis Cancer 119

Version of Record online: 18 JUL 2013 | DOI: 10.1002/cncr.28259

Analysis of Surveillance, Epidemiology, and End Results (SEER) Program data shows that glioblastoma patients who died in 2010 had lived with disease longer than patients who died in 2008. This improvement is hypothesized to be related to the availability of bevacizumab at the time of tumor progression for patients who died in 2010.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field